Review Article

Retrospective evaluation of the curative effect of traditional Chinese medicine on dry eye disease

San-Hua Su*, Tsung-Jung Ho*, Cheng-Chan Yang***

*Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan; **School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan

ABSTRACT

Dry eye disease (DED) is a multifactorial illness with an increasingly high global prevalence and multiple risk factors that widely influences patients’ daily lives. It is essential to identify treatments with few or no side effects for patients with DED. We have reviewed studies published from 2001 to 2020 that investigated traditional Chinese medicine (TCM) and integrated Chinese and Western medicine for DED treatment. Current Chinese medicines used in DED therapy were categorized into four types, namely anti-oxidants, anti-inflammatory agents, hormone-like agents, and cell-repairing agents. Compound herbs, including Chi-Ju-Di-Huang-Wan and Qiming granule, can effectively alleviate dry eye symptoms. Moreover, patients with DED who were treated with Western medicine combined with TCM experienced significantly magnified therapeutic effects and reasonable costs of treatment. In conclusion, TCM can be a promising approach for treating DED, and combined treatment with TC and Western drugs may represent a new strategy for improving the curative effect.

KEYWORDS: Dry eye disease, Integrated Chinese and Western medicine treatment, Traditional Chinese medicine

INTRODUCTION

Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and it is accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles according to the 2017 TFOS DEWS II global dry eye definition [1]. The pathophysiology of DED is associated with a multifactorial process that causes tear deficiency, excessive tear evaporation, and ocular surface cell damage, contributing to tear film imbalance and dry eye symptoms. The rising osmolarity of tears activates stress signaling pathways in ocular epithelial cells and immune cells, which produce innate inflammatory mediators (e.g., interleukin [IL]-1β, tumor necrosis factor [TNF]-α, and IL-6) that might further attract CD4+ T cells. A series of inflammatory reactions leads to injury of the cornea, conjunctiva, and lacrimal epithelial cells [2]. The prevalence of DED ranges from approximately 5%–50% among countries, with its incidence being highest in South East Asia and lowest in the USA and Europe [1,3]. According to the statistical data from the Taiwan National Health Insurance Research Database covering the period 2000–2013, the prevalence rates of DED in males and females were 6.81 and 16.16%, respectively. In addition, the incidence is highest in women aged 50–74 and men older than 75 [4]. In addition to age and gender, several DED risk factors have widely been investigated, such as the contact lens, arthritis, smoking, and drinking [5]. Based on data from the National Health Insurance of Taiwan covering 2004–2013, air pollution, such as carbon monoxide and nitrogen pollution, and rising temperatures were positively associated with the risk of DED [6]. A population-based study in Taiwan revealed that patients with DED had a higher risk of Sjögren’s syndrome [7]. In addition, presbyopia is related to the development of DED. The probability of a patient with presbyopia will develop DED after 5 years is 8.8%, which is 2-fold higher than in patients without presbyopia [4]. Osteoporosis is also a risk factor for the development of DED, and the subsequently worsening of vision in such patients could increase the probability of fall and bone fracture [8]. In addition, research has found...
that elderly women with DED and recurrent oral aphthae, especially those aged 50–69, might have an increased risk of oral cavity cancer [9].

The effects of DED on patients’ daily lives have received increasing attention. Therefore, the discovery of drugs with few or no side effects would have considerably high value for the treatment of DED. This review article examined articles published between 2001 and 2020 that reported Chinese medicine and the combined use of Chinese and Western medicines in patients with DED, including both single and compound herbs. The prospect of integrated Chinese and Western medicine was also discussed.

**Current Western Medicine Treatment**

Currently available DED treatments include artificial tears, aqueous secretagogues (e.g., diquafosol sodium), food additives (e.g., polyunsaturated fatty acids), anti-inflammatory drugs (e.g., rebamipide, cyclosporine), anti-oxidants, punctal plugs, and lifestyle intervention [10]. Patients with DED have higher rates of comorbidities, especially hypertension, diabetes mellitus, thyroid disease, cardiovascular diseases, cataract, and glaucoma, than those without DED. Consequently, medication use, including both ophthalmic agents and drugs to treat comorbidities (e.g., decongestants/vasoconstrictors, anxiolytics, beta-blockers), is higher in patients with DED than in those without DED. There is a need for new approaches or multidisciplinary teams to treat patients with DED according to their comorbidities and treatment history [11]. Potential strategies such as acupuncture, the short interfering RNA SYL1001, and nanomedicine therapy are other options for patients with DED who are unsatisfied with current treatments [12].

**Current Research on Traditional Chinese Medicine in the Treatment of Dry Eye Disease**

In this review, the traditional Chinese medicines (TCMs) used clinically in the treatment of DED are categorized into two types. The first type is single herbs including Cassiae semen, *Ophiopogonis japonicus*, Lycii Fructus, Achyranthis radix, *Buddleja officinalis*, *Bidens pilosa* L., *Schisandrae chinensis* fructus, *Liriope platyphylla*, and the active ingredients of Chinese herbs (curcumin, ferulic acid [FA], and kaempferol [KM]). The second type comprises compound formulations including Chi-Ju-Di-Huang-Wan, Zhibai Dihuang, Liuwei Dihuang, and Qiming granule. All of these treatments have proven efficacy based on clinical research or experience.

**Single-herb Chinese medicines**

**Anti-oxidants**

Cassiae semen, containing the vital compound emodin, plays an influential anti-oxidative role in the linoleic acid peroxidation system [13]. Because Cassiae semen and *O. japonicus* have been identified as anti-oxidants, oral anti-oxidant supplements containing these Chinese herbal additives might increase tear production, thereby ameliorating general dry eye symptoms by reducing oxidative stress damage [14].

Another Chinese herb, Lycii Fructus (Gou qi zhi), contains the anti-oxidants zeaxanthin and lutein [15]. Moreover, it had been reported to contain *Lycium barbarum* polysaccharide, which exerts anti-excitotoxic, anti-inflammatory, and anti-apoptotic effects. Through the mechanisms of anti-oxidation, neuroprotection, blood-retinal barrier protection, and immunomodulation, *Lycium barbarum* polysaccharide has a potent ameliorative effect on retinal disease in animal models of diseases and conditions such as glaucoma, ischemia/reperfusion injury, age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa [16,17]. Another report stated that Lycii Fructus can improve DED symptoms dose-dependently in rats by increasing the tear volume and protecting ocular surface cells, and no toxic effects were observed in the liver or kidneys [18].

Curcumin has multiple effects, acting as a natural anti-oxidant to scavenge reactive nitrogen species and reactive oxygen species or serving as an anti-inflammatory agent that promotes promote angiogenesis in the treatment of corneal diseases such as DED, conjunctivitis, pterygium, anterior uveitis, glaucoma, cataract, and diabetic retinopathy [19].

**Anti-inflammatory agents**

Achyranthis radix contains numerous anti-inflammatory molecules, such as saponins and phytocdyesones. It can improve irregularity of the corneal surface and simultaneously inhibit corneal epithelial cell death and increase goblet cell density, as noted in a rat model of DED induced by urban particulate matter [20].

One study reported that topically applied esculetin, which was extracted from the Chinese herb-drug “Qinpi,” inactivated the ERK1/2 pathway, which was correlated with chronic ocular surface inflammation and which enhanced the anti-inflammatory function of cyclosporine A, thereby improving DED symptoms in a rabbit dry eye model [21].

Another study found that the herbal extracts FA and KM can downregulate the expression of pro-inflammatory cytokines (IL-1B, IL-6, IL-8, and TNF-α) in human corneal epithelial cells [22]. FA is a component of *Angelicae sinensis* Radix with anti-oxidant effects [23]. Moreover, KM is present in *Ginkgo biloba* and propolis, and it has been reported to have anti-inflammatory, anti-oxidant, and anti-tumor activity [24]. Research illustrated that dropping a buffer solution containing 100 μM FA and 1 μM KM into the eyes of rabbits can increase tear secretion and repair corneal epithelial cells without irritant effects [22].

**Hormone-like agents**

The androgen receptor is widely expressed in ocular tissues such as lacrimal gland epithelial cells and the cornea [25]. Sexual hormone imbalance leads to the dysregulation of ocular structures, increasing the risk of DED, especially in women [26]. Androgen therapy might be a therapeutic option, but their side effects are undesirable. *B. officinalis* contain effective flavonoids, namely polyphenolic heterocyclic
compounds similar to androgens. Based on their structural similarities, certain flavonoids are agonists of membrane androgen receptors and exert androgen-like effects [27,28]. The therapeutic effects of \( B. \text{ officinalis} \) have been described in a series of studies. In vitro research illustrated that the expression of the STAT1 phosphoprotein can be upregulated through the biological effects of androgens after rat lacrimal gland epithelial cells were treated with \( B. \text{ officinalis} \)-containing plasma [29]. A study of castrated rats revealed that eye drops containing \( B. \text{ officinalis} \) extract can increase the Schirmer I test value, prolong the tear film break-up time value, and upregulate androgen receptor expression in the lacrimal gland compared with the findings in nontreated castrated rats [30]. Another study in castrated rabbits reported that the intragastric administration of \( B. \text{ officinalis} \) extract intensified TGF-\( \beta \)1 expression and reduced IL-1\( \beta \) and TNF-\( \alpha \) expression in the lacrimal gland, thereby diminishing local inflammation and damage in lacrimal epithelial cells caused by androgen deficiency [31].

The incidence of DED is high in postmenopausal and perimenopausal women [26]. Further, DED symptoms were reported in postmenopausal women who were tested using the questionnaires for the Ocular Surface Disease Index and affected their quality of life [32]. The effect of hormone therapy is controversial [33]. A study in rats illustrated that the Chinese herb \( B. \text{ pilosa} \), which contains androgen-like compound flavonoids, can relieve dry eye symptoms associated with androgen deficiency [34]. The study administered an anti-androgenic agent, finasteride, to a female animal model and observed significantly reduced expressions of the sex hormone receptors in the cornea and lacrimal gland [35]. Oral administration of \( B. \text{ pilosa} \) extract in rats with DED induced by finasteride promoted tear secretion, increased tear film stability, and reduced inflammation in the lacrimal gland by inhibiting inflammatory cytokine levels (IL-1\( \beta \), FasL, and TNF-\( \alpha \)) [34]. Although the above-mentioned studies can prove that the herbs have a therapeutic effect on androgen deficiency dry eye, further pharmacological testing to treat the DED situation in the menopausal state is warranted.

**Cell-repairing agents**

Xiaosheng prescription, comprising Rehmanniae Radix, \( A. \text{ sinensis} \) Radix, Codonopsis Radix, \( S. \text{ chinensis} \) Fructus, Ophiopogonis Radix, Bupleuri Radix, Menthae Haplocalycis Herba, and Paeoniae Radix Alba, are used to treat DED in patients with liver stagnation and yin deficiency in the Eye Hospital of the China Academy of Chinese Medicine Sciences. Human corneal epithelial cells treated with Xiaosheng prescription have a higher survival rate and lower lactate dehydrogenase release and apoptosis rates in hypertonic solution than model cells. Furthermore, mice with xerophthalmia mouse induced by scopolamine hydrobromide exhibit increased tear secretion after the oral administration of Xiaosheng prescription extract solution. Schisandrin and schisantherin A might be vital ingredients that effectively protect human corneal epithelial cells against hypertonic injury [36].

\( L. \text{ platyphylla} \) has displayed wound-healing and anti-inflammatory effects in the clinic. One study revealed that \( L. \text{ platyphylla} \) can protect against ocular damage induced by particulate matter exposure. Topical \( L. \text{ platyphylla} \) extract applied in rats with DED induced by urban particulate matter increased tear volume, decreased corneal epithelial cell injury and apoptosis, restored the corneal mucin-4 layer, and maintained the conjunctival goblet cell density [37].

**Chinese medicine compound herbs**

Chi-Ju-Di-Huang-Wan, including the formulation of Liu Wei Di Huang Wan plus Fructus Lycii and Hos Chrysanthemi, is the most frequently used TCM for DED. One study of patients diagnosed with DED revealed that Chi-Ju-Di-Huang-Wan can stabilize the tear film and decrease the degeneration of corneal epithelial cells [38].

The combination of the Chinese herbal formulas Chi-Ju-Di-Huang-Wan and Si Wu Tang can increase tear secretion by inhibiting the upregulation of tear vascular endothelium growth factor, and no adverse effects were noted in patients with DED after 3 months of oral treatment [39].

Qiming granule, a broadly used compound in China composed of Radix Astragali, Radix Puerariae Lobatae, Radix Rehmanniae, Fructus Lycii, Semen Cassiae, Fructus Leonuri, Pollen Typhae, and Hirudo, has been reported to have remarkable efficacy in the treatment of DED and other eye diseases. A meta-analysis revealed that Qiming granule can significantly extend the tear film break-up time, enhance tear secretion, and repair corneal damage in patients with DED [40].

**INTEGRATED CHINESE AND WESTERN MEDICINE IN DRY EYE DISEASE TREATMENT**

Currently available DED treatments manage tear insufficiency, eyelid abnormalities, and ocular inflammation, and the options include surgical approaches, dietary modification, local environmental considerations, complementary medicines, and staged management algorithms. However, there is a need for more convincing evidence of the efficacy of these treatments and alternative therapies [41]. Based on the unsatisfactory effects of DED treatments, a study of patients treated with artificial tears plus acupuncture recorded significantly improves of dry eye symptoms and decreased conjunctival redness after 1 month compared with the findings for artificial tears alone. However, no difference was noted after 4 weeks between the effects of artificial tears plus herbal medicine (Qi Ju Gan Lu Yin) and artificial tears alone. Moreover, the levels of cytokines in tears such as TNF-\( \alpha \) and IL-4 are reduced after treatment with artificial tears and acupuncture. In addition, tear IL-12 concentrations can be reduced by combined treatment with artificial tears and herbal medicine. Consequently, combined treatment with artificial tears and acupuncture can effectively improve dry eye symptoms. More research is needed to determine the optimal treatment time and identify the most potent combinations of artificial tears and herbal medicine [42].

Patients with insulin-dependent and noninsulin-dependent diabetes mellitus are susceptible to DED because of poor diabetic control and peripheral neuropathy, which cause ocular
surface changes and tear insufficiency [43,44]. A clinical study found that corneal sensitivity, superficial punctate keratopathy, and tear quantity could be significantly improved by the administration of the Chinese herb Goshajinkigan (also called Ji-Sheng-Shen-Qi-Wan) in patients with insulin-dependent diabetes mellitus who received insulin for >5 years [45]. Another study found that combined treatment with Chinese and Western medicine in patients with diabetes-induced xerophthalmia reduced the expression of inflammatory factors (IL-1, IL-8, and TNF-α), enhanced tear production, and decreased corneal injuries [46].

In Singapore, the prevalence of complementary and alternative medicine use is approximately 76% over a 12-month period, and TCM was the most commonly used (88%) complementary medicine [47]. A questionnaire-based study revealed that 87% of TCM practitioners slightly or strongly believed that TCM is an adequate therapy for treating DED. The TCM cost per episode for acupuncture and herbal treatment once to twice a week is approximately S$20–50 compared with S$60–100 per physician consultation for Western medicine with additional drug costs [48].

Consequently, integrated Chinese and Western medicine treatment has great potential and utility. Additional research is needed to verify the efficacy of combination treatment.

**CONCLUSION**

TCM still has great applicability in the treatment of DED. TCM, which has fewer side effects, consists of herbal medicine, acupuncture, and moxibustion according to patients’ different constitutions. In addition, integrated Chinese and Western medicine treatment can further augment the therapeutic effect. Consequently, TCM represents a new treatment option for DED. As anti-oxidants, anti-inflammatory agents, hormone-like compounds, or cell-repairing compounds, herbal medicines represent affordable, safe, and effective therapies for DED. In future, integrated Chinese and Western medicine treatment can represent a more effective treatment option for DED.

**Financial support and sponsorship**

The Buddhist Tzu Chi Medical Foundation grants (TCMF-CWP 109-02) supported Department of Traditional Chinese Medicine, Hualien Tzu Chi Hospital, Hualien, Taiwan.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Craig JP, Nichols KK, Akpek Ek, Caffery B, Dua HS, Joo CK, et al. TFO8 DEWS II definition and classification report. Ocul Surf 2017;15:276-83.
2. Pfleger SC, de Paiva CS. The pathophysiology of dry eye disease: What we know and future directions for research. Ophthalmology 2017;124:S4-S13.
3. Buckley RJ. Assessment and management of dry eye disease. Eye (Lond) 2018;32:200-3.
4. Mai EL, Lin CC, Lian I, Liao R, Chen M, Chang C. Population-based study on the epidemiology of dry eye disease and its association with presbyopia and other risk factors. Int Ophthalmol 2019;39:2731-9.
5. Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, et al. Dry eye in the beaver dam offspring study: Prevalence, risk factors, and health-related quality of life. Am J Ophthalmol 2014;157:799-806.
6. Zhong YJ, Lee YC, Hsieh CJ, Tseng CC, Yin LM. Association between dry eye disease, air pollution and weather changes in Taiwan. Int J Environ Res Public Health 2018;15:2269-78.
7. Yen JC, Hsu CA, Li YC, Hsu MH. The prevalence of dry eye syndrome’s and the likelihood to develop Sjögren’s syndrome in Taiwan: A population-based study. Int J Environ Res Public Health 2015;12:7647-55.
8. Jeng VT, Lin SY, Hu HY, Lee OK, Kuo LL. Osteoporosis and dry eye syndrome: A previously unappreciated association that may alert active prevention of fall. PLoS One 2018;13:e0207008.
9. Qin L, Kao YW, Lin YL, Peng BY, Deng WP, Chen TM, et al. Combination of recurrent oral aphtha and dry eye syndrome may constitute an independent risk factor for oral cavity cancer in elderly women. Cancer Manag Res 2018;10:3273-81.
10. Kojima T, Dogru M, Kawashima M, Nakamura S, Tsukuba K. Advances in the diagnosis and treatment of dry eye. Prog Retin Eye Res 2020;78:100842.
11. Dana R, Bradley JL, Guarin A, Pinovea I, Stillman IO, Evans AM, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol 2019;202:47-54.
12. Kuo VK, Lin IC, Chien LN, Lin TY, How VT, Chen KH, et al. Dry eye disease: A review of epidemiology in Taiwan, and its clinical treatment and merits. J Clin Med 2019;8:1227-51.
13. Yen GC, Chen HW, Duh PD. Extraction and identification of an antioxidative component from Jue Ming Zi (Cassia tora L.). J Agri Food Chem 1998;46:820-4.
14. Huang YJ, Yeh PT, Hou YC. A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome. Clin Ophthalmol 2016;10:813-20.
15. Leung I, Tso M, Li W, Lam T. Absorption and tissue distribution of zeaxanthin and lutein in rhesus monkeys after taking Fructus lycii (Gou Qi Zi) extract. Invest Ophthalmol Vis Sci 2001;42:466-71.
16. Manthey AL, Chiu K, So KF. Effects of lycium barbarum on the visual system. Int Rev Neurobiol 2017;135:1-27.
17. Xing X, Liu F, Xiao J, So KF. Neuro-protective mechanisms of lycium barbarum. Neuromolecular Med 2016;18:253-63.
18. Chien KJ, Horng CT, Huang YS, Hsieh YH, Wang CJ, Yang JS, et al. Effects of lycium barbarum (goji berry) on dry eye disease in rats. Mol Med Rep 2018;17:809-18.
19. Radomska-Leśniewska DM, Osiecka-Iwan A, Hye A, Góźdz A, Dąbrowska AM, Skopiński P. Therapeutic potential of curcumin in eye diseases. Cent Eur J Immunol 2019;44:181-9.
20. Lee TG, Hyun SW, Jo K, Park B, Lee IS, Song SJ, et al. Achyranthis radix extract improves urban particulate matter-induced dry eye disease. Int J Med Rep 2018;17:700-8.
21. Jiang D, Liu X, Hu J. Topical administration of esculetin as a potential therapy for experimental dry eye syndrome. Eye (Lond) 2017;31:1724-32.
22. Chen YH, Wang CY, Shih CH, Wang JY, Tseng CL, Fang HW, et al. Herbal supplement in a buffer for dry eye syndrome treatment. Int J Mol Sci 2017;18:1697-713.
23. Wang LY, Tang YP, Liu X, Zhu M, Tao WW, Li WX, et al. Effects of ferulic acid on antioxidant activity in Angelicae Sinensis Radix, Chuanxiong Rhizoma, and their combination. Chin J Nat Med 2015;13:401-8.
24. Rajendra P, Rengarajan T, Nandakumar N, Palaniswami R, Nishigaki Y, Nishigaki I. Kaempferol, a potential cytostatic and cure for inflammatory disorders. Eur J Med Chem 2014;86:103-12.
25. Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand 2000;78:146-53.

26. Truong S, Cole N, Stapleton F, Golebiowski B. Sex hormones and the dry eye. Clin Exp Optom 2014;97:324-36.

27. Xie G, Xu Q, Li R, Shi L, Han Y, Zhu Y, et al. Chemical profiles and quality evaluation of Buddleja officinalis flowers by HPLC-DAD and HPLC-Q-TOF-MS/MS. J Pharm Biomed Anal 2019;164:283-95.

28. Nifli AP, Bosson-Kouamé A, Papadopoulou N, Kogia C, Kampa M, Castagnino C, et al. Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. Exp Cell Res 2005;309:329-39.

29. Wang F, Peng QH, Yao XL, Wu QL, Li D. Effect of Buddleia flavonoids drug-containing plasma on the expression of STAT1 phosphoprotein in lacrimal gland epithelial cells in vitro. Int J Ophthalmol 2010;3:32-5.

30. Peng QH, Yao XL, Wu QL, Tan HY, Zhang JR. Effects of extract of Buddleja officinalis eye drops on androgen receptors of lacrimal gland cells of castrated rats with dry eye. Int J Ophthalmol 2010;3:43-8.

31. Yao XL, Peng QH, Peng J, Tan HY, Wu QL, Wu DL, et al. Effects of extract of Buddleja officinalis on partial inflammation of lacrimal gland in castrated rabbits with dry eye. Int J Ophthalmol 2010;3:114-9.

32. Garcia-Alfaro P, Garcia S, Rodriguez I, Vergés C. Dry eye disease symptoms and quality of life in perimenopausal and postmenopausal women. Climacteric 2020;2020:1-11.

33. Peck T, Olsakovsky L, Aggarwal S. Dry eye syndrome in menopause and perimenopausal age group. J Midlife Health 2017;8:51-4.

34. Zhang C, Li K, Yang Z, Wang Y, Si H. The effect of the aqueous extract of Bidens Pilosa L. on androgen deficiency dry eye in rats. Cell Physiol Biochem 2016;39:266-77.

35. Singh S, Moksha L, Sharma N, Titiyal JS, Biswas NR, Velpandian T. Development and evaluation of animal models for sex steroid deficient dry eye. J Pharmacol Toxicol Methods 2014;70:29-34.

36. Wu H, Lin L, Du X, Zhang L, Yin X, Dong X, et al. Study on the potential effective ingredients of Xiaosheng prescription for dry eye disease. Biomed Pharmacother 2020;127:110051.

37. Song SJ, Hyun SW, Lee TG, Park B, Jo K, Lee JS, et al. Topical application of Liriope platyphylla extract attenuates dry eye syndrome induced by particulate matter. J Ophthalmol 2019;2019:1429548.

38. Chang YH, Lin HJ, Li WC. Clinical evaluation of the traditional Chinese prescription Chi-Ju-Di-Huang-Wan for dry eye. Phytother Res 2005;19:349-54.

39. Chao WW, Tan SQ, Liu JH, Chen MM, Shiu HW, Chao HM. Dry eye: The effect of Chi-Ju-Di-Huang-Wan Plus Si Wu Tang and the underlying mechanism. J Altern Complement Med 2020;26:138-46.

40. Yang M, Hu Z, Yue R, Yang L, Zhang B, Chen Y. The efficacy and safety of qiming granule for dry eye disease: A systematic review and meta-analysis. Front Pharmacol 2020;11:580.

41. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf 2017;15:575-628.

42. Tong L, Huo HM, Hou A, Acharya RU, Tan JH, Wei QP, et al. Acupuncture and herbal formulation compared with artificial tears alone: Evaluation of dry eye symptoms and associated tests in randomised clinical trial. BMJ Open Ophthalmol 2018;3:e000150.

43. Dogra M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology 2001;108:586-92.

44. Goebls M. Tear secretion and tear film function in insulin dependent diabetics. Br J Ophthalmol 2000;84:19-21.

45. Nagaki Y, Hayasaka S, Hayasaka Y, Kadoi C, Sekiya N, Terasawa K, et al. Effects of goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus. Am J Chin Med 2003;31:103-9.

46. Wu SQ, Dai Q, Xu JL, Sheng WY, Xu QB, Zhong LY. Combined effect of traditional Chinese and Western medicine on inflammatory factors in patients with diabetes-induced xerophthalmia. Genet Mol Res 2016;15:gnr15049030.

47. Lim MK, Sadarangani P, Chan HL, Heng JY. Complementary and alternative medicine use in multiracial Singapore. Complement Ther Med 2005;13:16-24.

48. Lan W, Lee SY, Lee MX, Tong L. Knowledge, attitude, and practice of dry eye treatment by institutional Chinese physicians in Singapore. ScientificWorldJournal 2012;2012:923059.